# VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer

> **NCT01486329** · PHASE1 · COMPLETED · sponsor: **Vaximm GmbH** · enrollment: 72 (actual)

## Conditions studied

- Stage IV Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** VXM01
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT01486329
- **Lead sponsor:** Vaximm GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2014-10
- **Final completion:** 2014-12
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2015-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01486329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01486329, "VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01486329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*